Retrospective analysis of 2D patient-specific IMRT verifications

2005 ◽  
Vol 32 (4) ◽  
pp. 838-850 ◽  
Author(s):  
Nathan L. Childress ◽  
R. Allen White ◽  
Charles Bloch ◽  
Mohammad Salehpour ◽  
Lei Dong ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Patient Specific

scholarly journals True Kinematic Alignment Is Applicable in 44% of Patients Applying Restrictive Indication Criteria—A Retrospective Analysis of 111 TKA Using Robotic Assistance

2021 ◽  
Vol 11 (7) ◽  
pp. 662
Author(s):  
Kim Huber ◽  
Bernhard Christen ◽  
Sarah Calliess ◽  
Tilman Calliess
Keyword(s):  
Soft Tissue ◽  
Retrospective Analysis ◽  
Patient Specific ◽  
Kinematic Alignment ◽  
Postoperative Phase ◽  
Robotic Assistance ◽  
Component Position ◽  
Joint Stability ◽  
Robotic Assisted ◽  
Primary Tkas

Introduction: Image-based robotic assistance appears to be a promising tool for individualizing alignment in total knee arthroplasty (TKA). The patient-specific model of the knee enables a preoperative 3D planning of component position. Adjustments to the individual soft-tissue situation can be done intraoperatively. Based on this, we have established a standardized workflow to implement the idea of kinematic alignment (KA) for robotic-assisted TKA. In addition, we have defined limits for its use. If these limits are reached, we switch to a restricted KA (rKA). The aim of the study was to evaluate (1) in what percentage of patients a true KA or an rKA is applicable, (2) whether there were differences regarding knee phenotypes, and (3) what the differences of philosophies in terms of component position, joint stability, and early patient outcome were. Methods: The study included a retrospective analysis of 111 robotic-assisted primary TKAs. Based on preoperative long leg standing radiographs, the patients were categorized into a varus, valgus, or neutral subgroup. Initially, all patients were planned for KA TKA. When the defined safe zone had been exceeded, adjustments to an rKA were made. Intraoperatively, the alignment of the components and joint gaps were recorded by robotic software. Results and conclusion: With our indication for TKA and the defined boundaries, “only” 44% of the patients were suitable for a true KA with no adjustments or soft tissue releases. In the varus group, it was about 70%, whereas it was 0% in the valgus group and 25% in the neutral alignment group. Thus, significant differences with regard to knee morphotypes were evident. In the KA group, a more physiological knee balance reconstructing the trapezoidal flexion gap (+2 mm on average laterally) was seen as well as a closer reconstruction of the surface anatomy and joint line in all dimensions compared to rKA. This resulted in a higher improvement in the collected outcome scores in favor of KA in the very early postoperative phase.

Retrospective analysis of portal dosimetry pre-treatment quality assurance of intracranial SRS/SRT VMAT treatment plans

2021 ◽  
pp. 1-13
Author(s):  
Ernest Osei ◽  
Sarah Graves ◽  
Johnson Darko
Keyword(s):  
Quality Assurance ◽  
Retrospective Analysis ◽  
Low Dose ◽  
Treatment Quality ◽  
Patient Specific ◽  
Portal Dosimetry ◽  
Treatment Plans ◽  
The Mean ◽  
Pre Treatment ◽  
Action Levels

Abstract Background: The complexity associated with the treatment planning and delivery of stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) volumetric modulated arc therapy (VMAT) plans which employs continuous dynamic modulation of dose rate, field aperture and gantry speed necessitates diligent pre-treatment patient-specific quality assurance (QA). Numerous techniques for pre-treatment VMAT treatment plans QA are currently available with the aid of several different devices including the electronic portal imager (EPID). Although several studies have provided recommendations for gamma criteria for VMAT pre-treatment QA, there are no specifics for SRS/SRT VMAT QA. Thus, we conducted a study to evaluate intracranial SRS/SRT VMAT QA to determine clinical action levels for gamma criteria based on the institutional estimated means and standard deviations. Materials and methods: We conducted a retrospective analysis of 118 EPID patient-specific pre-treatment QA dosimetric measurements of 47 brain SRS/SRT VMAT treatment plans using the integrated Varian solution (RapidArcTM planning, EPID and Portal dosimetry system) for planning, delivery and EPID QA analysis. We evaluated the maximum gamma (γmax), average gamma (γave) and percentage gamma passing rate (%GP) for different distance-to-agreement/dose difference (DTA/DD) criteria and low-dose thresholds. Results: The gamma index analysis shows that for patient-specific SRS/SRT VMAT QA with the portal dosimetry, the mean %GP is ≥98% for 2–3 mm/1–3% and Field+0%, +5% and +10% low-dose thresholds. When applying stricter spatial criteria of 1 mm, the mean %GP is >90% for DD of 2–3% and ≥88% for DD of 1%. The mean γmax ranges: 1·32 ± 1·33–2·63 ± 2·35 for 3 mm/1–3%, 1·57 ± 1·36–2·87 ± 2·29 for 2 mm/1–3% and 2·36 ± 1·83–3·58 ± 2·23 for 1 mm/1–3%. Similarly the mean γave ranges: 0·16 ± 0·06–0·19 ± 0·07 for 3 mm/1–3%, 0·21 ± 0·08–0·27 ± 0·10 for 2 mm/1–3% and 0·34 ± 0·14–0·49 ± 0·17 for 1 mm/1–3%. The mean γmax and mean γave increase with increased DTA and increased DD for all low-dose thresholds. Conclusions: The establishment of gamma criteria local action levels for SRS/SRT VMAT pre-treatment QA based on institutional resources is imperative as a useful tool for standardising the evaluation of EPID-based patient-specific SRS/SRT VMAT QA. Our data suggest that for intracranial SRS/SRT VMAT QA measured with the EPID, a stricter gamma criterion of 1 mm/2% or 1 mm/3% with ≥90% %GP could be used while still maintaining an in-control QA process with no extra burden on resources and time constraints.

A retrospective analysis of the effect of patient-specific factors on voriconazole concentrations in oncology patients

2011 ◽  
Vol 18 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Lindsey R Lombardi ◽  
Todd A Miano ◽  
Jennifer L Davis ◽  
Steven C Morgan ◽  
Steven C Goldstein ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Patient Specific ◽  
Oncology Patients ◽  
Specific Factors

scholarly journals EP-1394: VMAT patient-specific QA with 2D-array seven29/Octavius system: a retrospective analysis on 1000 patients

2015 ◽  
Vol 115 ◽  
pp. S752-S753
Author(s):  
S. Cilla ◽  
P. Viola ◽  
M. Craus ◽  
F. Deodato ◽  
G. Macchia ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Patient Specific ◽  
System A ◽  
Patient Specific Qa ◽  
2D Array

scholarly journals A retrospective analysis of patient-specific factors on voriconazole clearance

2016 ◽  
Vol 2 (1) ◽  
Author(s):  
Satoshi Dote ◽  
Maki Sawai ◽  
Ayumu Nozaki ◽  
Kazumasa Naruhashi ◽  
Yuka Kobayashi ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Patient Specific ◽  
Specific Factors

scholarly journals SURVIVALAND PROGNOSTIC FACTORS FOR GLIOBLASTOMA MULTIFORME: A RETROSPECTIVE SINGLE INSTITUTIONAL STUDY

2020 ◽  
pp. 1-3
Author(s):  
Maneet Gill ◽  
Chinmaya Srivastava ◽  
Sudhanshu Agarwal ◽  
Lokesh Gautam
Keyword(s):  
Overall Survival ◽  
Survival Analysis ◽  
Prognostic Factors ◽  
Glioblastoma Multiforme ◽  
Retrospective Analysis ◽  
Clinical Features ◽  
Median Survival ◽  
Survival Outcome ◽  
Patient Specific ◽  
Entire Cohort

OBJECTIVE The purpose of the present retrospective analysis was to present and discuss clinical features (Patient specific and tumour specific) and various prognostic factors that predict the survival of the patients with Glioblastoma multiforme (GBM) and to compare the results with pre-existing literature. MATERIALS &METHODS A single institutional data of 221 patients of GBM was reviewed from 2014 to 2018. Data regarding patients’ factor,tumour factor and survival analysis were collected and based on the above factor’s survival outcome was calculated. RESULTS A total of 221 patients were analysed. 197 patients underwent resection and 24 patients underwent biopsy (Open or stereotactic). Patients had a mean age of 56.5 years at the time of diagnosis. Median survival in patients < 50 years was 9.21 months and > 50 years was 4.56 months. The overall survival was 4.27% for the entire cohort at the end of two years. CONCLUSION In patients with GBM overall survival and prognosis remains dismal.Standard treatment includes resection followed bychemo-radiation which has improved the overall survivaloutcome. However, the prognosis continues to remains poor.

Sign in / Sign up

Export Citation Format

Share Document